REPLIGEN CORPORATION (NASDAQ:RGEN) Files An 8-K Results of Operations and Financial Condition

Item2.02. Results of Operations and Financial Condition.

On May4, 2017, Repligen Corporation announced its financial
results for the first quarter ended March31, 2017. The full text
of the press release issued in connection with the announcement
is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K and the exhibit attached hereto
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly
set forth by specific reference in such a filing.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits

About REPLIGEN CORPORATION (NASDAQ:RGEN)

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug. The Company also supplies several growth factor products, Alternating Tangential Flow (ATF) System products and cell filtration products used to increase cell culture productivity during the bioproduction process. The Company has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. The Company manufactures and sells Protein A and growth factors to life sciences companies under long-term supply agreements and sells its chromatography columns, as well as media and quality test kits.

REPLIGEN CORPORATION (NASDAQ:RGEN) Recent Trading Information

REPLIGEN CORPORATION (NASDAQ:RGEN) closed its last trading session down -0.49 at 35.80 with 220,095 shares trading hands.